Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma

Urology

Volumn 48, Issue 5, 1996, Pages 692-695

  Seaman, Eric ^b   Goluboff, Erik T ^b   Ross, Susan ^b   Sawczuk, Ihor S ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CIMETIDINE; OKT 3;

ADOPTIVE IMMUNOTHERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; T LYMPHOCYTE;

ALKALINE PHOSPHATASE; BONE NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0343031683     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00236-1     Document Type: Article

References (13)

1. 1. Swanson DA, Orovan WL, Johnson DE, and Giacco G: Osseous metastases secondary to renal cell carcinoma. Urology 18: 556-561, 1981.
2. 2. Middleton AW Jr: Indications for and results of nephrectomy for metastatic renal cell carcinoma. Urol Clin North Am 7: 711-717, 1980.
3. 3. Fritzche PJ, and Millar C: Multimodality approach to staging renal cell carcinoma. Urol Radiol 14: 3-7, 1992.
4. 4. Blacher E, Johnson DE, and Haynie TP: Value of routine radionuclide bone scans in renal cell carcinoma. Urology 26: 432-434, 1985.
5. 5. Campbell RJ, Broaddus SB, and Leadbetter GW Jr: Staging of renal cell carcinoma: cost effectiveness of routine preoperative bone scans. Urology 25: 326-329, 1985.
6. 6. Lindner A, Goldman DG, and DeKernion JB: Cost effective analysis of prenephrectomy radioisotope scans in renal cell carcinoma. Urology 22: 127-129, 1983.
7. 7. Benson MA, Haaga JR, and Resnick MI: Staging renal carcinoma. What is sufficient? Arch Surg 124: 71-73, 1989.
8. 8. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawczuk IS, Ross S, and Krane RJ: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335: 994-998, 1990.
9. 9. Wingo PA, Tong T, and Bolden S: Cancer statistics, 1995. CA 45: 8-30, 1995.
10. 10. Jones GW: Renal cell carcinoma. CA 32: 280-285, 1982.
11. 11. Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, Huang WL, Grundmann E, Eder M, Zwicknagl M, et al: Metastatic patterns of renal carcinoma. An analysis of 687 necropsies. J Cancer Res Clin Oncol 114: 605-612, 1988.
12. 12. DeKernion JB, Ramming KP, and Smith RB: The natural history of metastatic renal cell carcinoma. A computer analysis. J Urol 120: 148-152, 1978.
13. 13. Atlas I, Kwan D, and Stone N: Value of serum alkaline phosphatase and radionuclide bone scans in patients with renal cell carcinoma. Urology 38: 220-222, 1991.